The acute technical success of percutaneous transluminal angioplasty (PTA) has been improved with the use of intravascular stents. However, stent placement has led to the development of an increased myointimal hyperplastic response leading to late reduction in vessel lumen. Restenosis (≥50% reduction in reference lumen diameter) rates for coronary angioplasty and stenting are reported between 20% and 50% at 1 year. Several studies are currently evaluating novel delivery of antiproliferative agents to prevent neointimal hyperplasia. The authors review the mechanism of neointimal hyperplasia as it relates to stent placement and discuss recent and ongoing trials evaluating intravascular brachytherapy and drug-eluting stent technology in the inhibition of restenotic lesions.
Get full access to this article
View all access options for this article.
References
1.
1. Gruntzig AR, Senning A, Siegenthaler WE: Nonoperative dilatation of coronary-artery stenosis: Percutaneous transluminal coronary angioplasty. N Engl J Med301:61-68, 1979.
2.
2. Gruentzig AR, King SB III, Schlumpf M, et al: Longterm follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. N Engl J Med316:1127-1132, 1987.
3.
3. Nobuyoshi M, Kimura T, Nosaka H, et al: Restenosis after successful percutaneous transluminal coronary angioplasty: Serial angiographic follow-up of 229 patients. J Am Coll Cardiol12:616-623, 1988.
4.
4. Holmes DR Jr, Van Raden MJ, Reeder GS, et al: Return to work after coronary angioplasty: A report from the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry Design of comparative clinical studies of percutaneous transluminal coronary angioplasty using estimates from the Coronary Artery Surgery Study. Am J Cardiol53:48C-51C, 1984.
5.
5. Fischman DL, Leon MB, Baim DS, et al: A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med331:496-501, 1994.
6.
6. Al Suwaidi J, Berger PB, Holmes DR Jr: Coronary artery stents. JAMA284:1828-1836, 2000.
7.
7. Serruys PW, de Jaegere P, Kiemeneij F, et al: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med331:489-495, 1994.
8.
8. Cutlip DE, Chauhan MS, Baim DS, et al: Clinical restenosis after coronary stenting: Perspectives from multicenter clinical trials. J Am Coll Cardiol40:2082-2089, 2002.
9.
9. Isles CG, Robertson S, Hill D: Management of renovascular disease: A review of renal artery stenting in ten studies. QJM92:159-167, 1999.
10.
10. Kandarpa K, Becker GJ, Hunink MG, et al: Transcatheter interventions for the treatment of peripheral atherosclerotic lesions: Part I. J Vasc Interv Radiol12:683-695, 2001.
11.
11. Lee ES, Steenson CC, Trimble KE, et al: Comparing patency rates between external iliac and common iliac artery stents. J Vasc Surg31:889-894, 2000.
12.
12. Siskin GP, Englander M, Roddy S, et al: Results of iliac artery stent placement in patients younger than 50 years of age. J Vasc Interv Radiol13:785-790, 2002.
14. Oberhoff M, Herdeg C, Baumbach A, et al: Stentbased antirestenotic coatings (sirolimus/paclitaxel). Cathet Cardiovasc Interv55:404-408, 2002.
15.
15. Kandzari DE, Tcheng JE, Zidar JP: Coronary artery stents: Evaluating new designs for contemporary percutaneous intervention. Cathet Cardiovasc Interv56:562-576, 2002.
16.
16. Farb A, Sangiorgi G, Carter AJ, et al: Pathology of acute and chronic coronary stenting in humans. Circulation99:44-52, 1999.
17.
17. Barth KH, Virmani R, Froelich J, et al: Paired comparison of vascular wall reactions to Palmaz stents, Strecker tantalum stents, and Wallstents in canine iliac and femoral arteries. Circulation93:2161-2169, 1996.
18.
18. Schwartz RS, Huber KC, Murphy JG, et al: Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol19:267-274, 1992.
19.
19. Schillinger M, Exner M, Mlekusch W, et al: Balloon angioplasty and stent implantation induce a vascular inflammatory reaction. J Endovasc Ther9:59-66, 2002.
20.
20. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, et al: Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J21:1152-1158, 2000.
21.
21. Schillinger M, Haumer M, Schlerka G, et al: Restenosis after percutaneous transluminal angioplasty in the femoropopliteal segment: The role of inflammation. J Endovasc Ther8:477-483, 2001.
22.
22. Schillinger M, Exner M, Mlekusch W, et al: Inflammatory response to stent implantation: Differences in femoropopliteal, iliac, and carotid arteries. Radiology224:529-535, 2002.
23.
23. Gallino A, Mahler F, Probst P, et al: Percutaneous transluminal angioplasty of the arteries of the lower limbs: A 5-year follow-up. Circulation70:619-623, 1984.
24.
24. Krepel VM, van Andel GJ, van Erp WF, et al: Percutaneous transluminal angioplasty of the femoropopliteal artery: Initial and long-term results. Radiology156:325-328, 1985.
25.
25. Matsi PJ, Manninen HI, Vanninen RL, et al: Femoropopliteal angioplasty in patients with claudication: Primary and secondary patency in 140 limbs with 1-3-year follow-up. Radiology191:727-733, 1994.
26.
26. Fischer-Dzoga K, Dimitrievich GS, Griem ML: Radiosensitivity of vascular tissue. II. Differential radiosensitivity of aortic cells in vitro. Radiat Res99:536-546, 1984.
27.
27. Hansrani M, Overbeck K, Smout J, et al: Intravascular brachytherapy: A systematic review of its role in reducing restenosis after endovascular treatment in peripheral arterial disease. Eur J Vasc Endovasc Surg24:377-382, 2002.
29. Coen VL, Knook AH, Wardeh AJ, et al: Endovascular brachytherapy in coronary arteries: The Rotterdam experience. Cardiovasc Radiat Med2:42-50, 2000.
30.
30. Teirstein PS, Massullo V, Jani S, et al: Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med336:1697-1703, 1997.
31.
31. Teirstein PS, Massullo V, Jani S, et al: Three-year clinical and angiographic follow-up after intracoronary radiation: Results of a randomized clinical trial. Circulation101:360-365, 2000.
32.
32. Liermann D, Kirchner J, Bauernsachs R, et al: Brachytherapy with iridium-192 HDR to prevent restenosis in peripheral arteries. An update. Herz23:394-400, 1998.
33.
33. Minar E, Pokrajac B, Maca T, et al: Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: Results of a prospective randomized study. Circulation102:2694-2699, 2000.
34.
34. Pokrajac B, Minar E, Kirisits C, et al: Present status of endovascular brachytherapy in peripheral arteries. Herz27:56-61, 2002.
35.
35. Sapirstein W, Zuckerman B, Dillard J: FDA approval of coronary-artery brachytherapy. N Engl J Med344:297-299, 2001.
36.
36. Holmes DR Jr, Savage M, LaBlanche JM, et al: Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation106: 1243-1250, 2002.
37.
37. Edelman ER, Adams DH, Karnovsky MJ: Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci USA87:3773-3777, 1990.
38.
38. Klugherz BD, Llanos G, Lieuallen W, et al: Twentyeight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis13:183-188, 2002.
39.
39. Morice MC, Serruys PW, Sousa JE, et al: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med346:1773-1780, 2002.
40.
40. Degertekin M, Regar E, Tanabe K, et al: Sirolimus eluting stent in the treatment of atherosclerosis coronary artery disease. Minerva Cardioangiol50:405-418, 2002.
42. Farb A, Heller PF, Shroff S, et al: Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation104:473-479, 2001.
43.
43. Grube E, Silber S, Hauptmann KE, et al: TAXUS I: Sixand twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation107:38-42, 2003.
44.
44. Liistro F, Stankovic G, Di Mario C, et al: First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: Immediate and long-term clinical and angiographic outcome. Circulation105:1883-1886, 2002.
